India supplies a very large share of the world's generic medicines and a very small share of its new ones.
That sentence is the whole problem, and it is not a criticism. Indian pharmaceutical manufacturing is a genuine national achievement built on process chemistry — the skill of making a known molecule more cheaply and at greater scale than anyone else. But a company that competes on process has no reason to spend on discovery, because discovery is expensive, slow and usually fails, and the returns go to whoever holds the patent rather than to whoever manufactures best.
On 30 September 2026, the Department of Pharmaceuticals announced the results of the first call under the Promotion of Research and Innovation in Pharma MedTech Sector (PRIP) scheme — 41 projects approved for around ₹1,600 crore — and opened a second call with a new funding track aimed squarely at the stage where Indian pharma has historically not played.
What was approved
The ₹1,600 crore in government assistance is expected to catalyse a further ₹3,020 crore of private investment, taking total R&D spending across these projects to about ₹4,620 crore. That ratio — roughly ₹1.9 of private money for every ₹1 of public — is the scheme's central design claim, and it is the number to watch over time.
The portfolio breaks down as follows:
- By stage: 12 early-stage, 29 later-stage.
- By applicant: 19 by startups and MSMEs, 22 by large companies.
- By priority area: 27 under New Medicines, 5 under Complex Generics and Biosimilars, 9 under Novel Medical Devices.
Named participants include Biocon, Bharat Biotech, Sun Pharma, Wockhardt, Zydus, Mankind Pharma, Pandorum Technologies, Cellogen Therapeutics, Aurigene Oncology and Bugworks Research — a mix of established manufacturers and research-stage firms that tells you the scheme is not simply subsidising incumbents.
The projects themselves are worth listing, because they indicate the technical level being attempted: an antibacterial targeting multidrug-resistant Gram-negative infections; an exosome-based regenerative therapy for corneal disease; an in-vivo CAR-T platform; patient-derived breast cancer organoids; a programmable RNA-targeting antiviral technology; a portable plasmonic-PCR device for point-of-care infection diagnosis; and a microfluidic platform for tuberculosis detection.
Two of those deserve a note. Multidrug-resistant Gram-negative bacteria are the hardest part of the antimicrobial resistance problem, and almost no large pharmaceutical company works on new antibiotics any more — the economics are inverted, because a successful new antibiotic should be used as little as possible. A government willing to fund that is funding something the market will not. And in-vivo CAR-T attempts to re-engineer a patient's T cells inside the body rather than extracting, modifying and reinfusing them; if it works it removes the single largest cost driver in cell therapy, which currently makes CAR-T unaffordable at Indian prices.
The scheme's architecture
PRIP has a total outlay of ₹5,000 crore, in two components.
Component A — ₹700 crore establishes seven Centres of Excellence at the National Institutes of Pharmaceutical Education and Research (NIPERs) — at Mohali, Ahmedabad, Hyderabad, Guwahati, Kolkata, Hajipur and Raebareli. Each specialises: anti-viral and anti-bacterial drug discovery, medical devices, bulk drugs, flow chemistry, novel drug delivery systems, phytopharmaceuticals, biological therapeutics.
Component B — ₹4,250 crore provides direct financial assistance to startups, MSMEs and industry, across early-stage and late-stage projects. Early-stage projects may receive up to ₹5 crore; late-stage projects up to ₹100 crore, capped at 35% central funding.
Note the shape of that ladder, because it explains what was announced alongside the results.
The gap at the bottom
Between ₹5 crore for early-stage work and ₹100 crore for late-stage development there is a chasm. And drug discovery has its highest failure rate and its longest unfunded stretch precisely in the middle of that gap — after a molecule looks promising in a laboratory, and before it has the clinical data that would attract conventional investment.
The Department has now opened a New Discovery Track for startups and MSMEs, offering up to ₹50 crore per company, project or portfolio of projects, subject to a minimum of 25% co-funding from bona fide institutional investors. Eligible applicants are startups and MSMEs undertaking New Chemical Entity (NCE) or New Biological Entity (NBE) projects at Technology Readiness Levels 1, 2 or 3; the Department will support them to progress to no higher than TRL 6.
Four features of that design are deliberate and worth understanding.
It targets TRL 1-3 and stops at TRL 6. On the nine-point TRL scale, 1 to 3 run from basic principles observed to proof of concept; TRL 6 is a prototype demonstrated in a relevant environment. In drug terms the track funds the journey from an idea with laboratory support to a candidate ready for serious clinical development — and then hands off. The state is buying the part of the pipeline nobody else will buy, and declining to fund the part that commercial capital will. The same TRL logic governs the Technology Development Board's awards to ePlane and Agnikul, where the target ranges were TRL 6-9 and TRL 4-8 respectively.
It requires 25% institutional co-funding. This is a screening device, not a revenue measure. Requiring a professional investor to put money alongside the government means someone with a financial stake has done due diligence on the science. It also, as the Department says, "catalyses participation of institutional investors at an earlier stage" — the co-funding requirement is intended to teach Indian venture capital to price early-stage drug discovery, a thing it has had little occasion to learn.
It is restricted to startups and MSMEs. Large companies have retained earnings and can fund their own discovery if they choose; the market failure the track addresses is specific to small firms with good science and no balance sheet.
It funds a portfolio, not only a project. Drug discovery works on portfolio logic — most candidates fail, so the rational unit of investment is a basket rather than a single molecule. Allowing an applicant to seek support for a portfolio is a quietly sophisticated piece of scheme design.
The second call invites applications across three priority areas: New Medicines (including NCEs, NBEs and phytopharmaceutical drugs), Complex Generics and Biosimilars, and Novel Medical Devices. Under a strategic priority framework, enhanced support is available for neglected tropical diseases, rare diseases, antimicrobial resistance for India-priority pathogens, and pathogens with outbreak or pandemic potential — four categories defined by public health importance rather than market size, which is the point of having the state in the room.
The honest caveat
₹5,000 crore across the whole scheme is, in global pharmaceutical terms, a modest sum. A single new drug brought from discovery to market typically costs a multiple of the entire PRIP outlay. Large pharmaceutical companies spend more on R&D in a year than this scheme will disburse over its life.
So PRIP cannot buy India a discovery industry. What it can do is fund the stage at which Indian firms currently stop, build the institutional habits — co-investment, portfolio funding, TRL discipline — that a discovery industry requires, and produce a handful of assets that demonstrate the thing is possible here. Whether that happens is measurable, and the metric is not how much was disbursed. It is how many of these 41 projects reach clinical development, and whether private capital follows without a government cheque next to it.
🔑 Revision block
- 30 September 2026: Department of Pharmaceuticals (Ministry of Chemicals and Fertilizers) announced first call results under PRIP — 41 projects, about ₹1,600 crore.
- PRIP = Promotion of Research and Innovation in Pharma MedTech Sector.
- Expected to catalyse ₹3,020 crore of private investment → total R&D of about ₹4,620 crore.
- Portfolio: 12 early-stage, 29 later-stage; 19 by startups/MSMEs, 22 by large companies; 27 New Medicines, 5 Complex Generics and Biosimilars, 9 Novel Medical Devices.
- Total outlay ₹5,000 crore. Component A — ₹700 crore for 7 Centres of Excellence at NIPERs: Mohali, Ahmedabad, Hyderabad, Guwahati, Kolkata, Hajipur, Raebareli. Component B — ₹4,250 crore direct assistance: early-stage up to ₹5 crore, late-stage up to ₹100 crore capped at 35% central funding.
- New Discovery Track: up to ₹50 crore per company/project/portfolio; minimum 25% co-funding from bona fide institutional investors; for startups and MSMEs with NCE/NBE projects at TRL 1-3, supported to no higher than TRL 6.
- NCE = New Chemical Entity; NBE = New Biological Entity.
- Second call priority areas: New Medicines (NCEs, NBEs, phytopharmaceuticals), Complex Generics and Biosimilars, Novel Medical Devices.
- Strategic priority framework gives enhanced support for neglected tropical diseases, rare diseases, AMR for India-priority pathogens, and pathogens with outbreak or pandemic potential.
- Example projects: antibacterial for multidrug-resistant Gram-negative infections; exosome-based corneal therapy; in-vivo CAR-T; patient-derived breast cancer organoids; programmable RNA-targeting antiviral; portable plasmonic-PCR; microfluidic TB detection.
- Participants named: Biocon, Bharat Biotech, Sun Pharma, Wockhardt, Zydus, Mankind Pharma, Pandorum Technologies, Cellogen Therapeutics, Aurigene Oncology, Bugworks Research.
- The structural problem addressed: India competes on process chemistry (making known molecules cheaply), not on discovery (inventing new ones).
🎯 Practice MCQs
Q1. The PRIP scheme is implemented by the: (a) Department of Pharmaceuticals (b) Indian Council of Medical Research (c) Department of Science and Technology (d) Department of Biotechnology
→ (a) PRIP is run by the Department of Pharmaceuticals under the Ministry of Chemicals and Fertilizers. The DBT, ICMR and DST all fund health research but none administers this scheme.
Q2. The total financial outlay of the PRIP scheme is: (a) ₹1,600 crore (b) ₹5,000 crore (c) ₹4,250 crore (d) ₹700 crore
→ (b) ₹5,000 crore in total — of which ₹700 crore is Component A (Centres of Excellence) and ₹4,250 crore Component B (direct assistance). The ₹1,600 crore figure is what the first call actually approved.
Q3. Under Component A of PRIP, Centres of Excellence are being established at: (a) All India Institutes of Medical Sciences (b) Indian Institutes of Science Education and Research (c) Seven National Institutes of Pharmaceutical Education and Research (d) Council of Scientific and Industrial Research laboratories
→ (c) Seven CoEs at NIPERs — Mohali, Ahmedabad, Hyderabad, Guwahati, Kolkata, Hajipur and Raebareli — with a budget of ₹700 crore, each specialising in a priority area.
Q4. The new Discovery Track announced under PRIP offers financial assistance of up to: (a) ₹5 crore (b) ₹100 crore (c) ₹1,600 crore (d) ₹50 crore
→ (d) Up to ₹50 crore per company, project or portfolio. It sits deliberately between the existing ₹5 crore early-stage ceiling and the ₹100 crore late-stage ceiling, filling the gap where early drug discovery goes unfunded.
Q5. Eligibility for the new Discovery Track is restricted to projects at Technology Readiness Levels: (a) 1, 2 or 3 (b) 4 to 6 (c) 6 to 9 (d) 7 to 9
→ (a) The track is open to NCE/NBE projects at TRL 1, 2 or 3, and supports them to no higher than TRL 6. The state funds the pre-commercial stretch and hands off where private capital can take over.
Q6. The Discovery Track requires a minimum co-funding contribution of: (a) 25% from bona fide institutional investors (b) 50% from a state government (c) 35% from the Department of Pharmaceuticals (d) 10% from the applicant's own resources
→ (a) A minimum 25% co-funding from bona fide institutional investors is required. It functions as a screening device — a professional investor's money alongside the government's implies independent due diligence on the science.
Q7. 'NCE' and 'NBE' in the context of the scheme stand respectively for: (a) New Clinical Endpoint and New Biomedical Experiment (b) New Chemical Entity and New Biological Entity (c) Novel Compound Evaluation and Novel Bioassay Evaluation (d) New Combination Element and New Bioequivalence Entity
→ (b) New Chemical Entity and New Biological Entity — the two categories of genuinely novel therapeutic agent, as distinct from generics, complex generics and biosimilars.
Q8. India's pharmaceutical industry has historically competed principally on the strength of its: (a) Novel molecule discovery pipeline (b) Biologics patent portfolio (c) Process chemistry and manufacturing scale (d) Clinical trial infrastructure
→ (c) India's competitive advantage has been process chemistry and scale — making known molecules more cheaply than anyone else. The returns from discovery accrue to the patent holder, which is why a process-competitive industry has limited incentive to fund it.
Q9. Under PRIP's strategic priority framework, enhanced support is available for innovations addressing: (a) Only communicable diseases prevalent in India (b) Lifestyle diseases with the largest domestic market (c) Vaccines for export markets exclusively (d) Neglected tropical diseases, rare diseases, AMR priority pathogens, and pathogens with outbreak potential
→ (d) All four categories are defined by public health importance rather than market size — which is precisely the kind of research private capital under-provides, and therefore the case for public funding.
Q10. New antibiotics attract little private pharmaceutical investment principally because: (a) Regulatory approval is prohibited for novel antibiotic classes (b) A successful new antibiotic should be used as sparingly as possible, inverting the usual commercial logic (c) Antibiotics cannot be patented (d) Bacterial infections are no longer a significant cause of death
→ (b) The economics are inverted: good antimicrobial stewardship requires a new antibiotic to be reserved, not widely prescribed, so the drug that is most valuable clinically generates the least revenue. This market failure is why public funding of the multidrug-resistant Gram-negative problem matters.
📋 How this gets asked (PYQ pattern)
Science and technology questions in CDS reward a particular kind of preparation, and pharmaceutical policy sits at the intersection of three question types.
The first is scheme identification — which ministry or department runs a scheme, what its outlay is, and what its components are. PRIP belongs to the Department of Pharmaceuticals; the PLI schemes for pharmaceuticals and bulk drugs belong to the same department; the Technology Development Board sits under the Department of Science and Technology; BIRAC under the Department of Biotechnology. Keeping the funder straight is half the question.
The second is institutional acronyms: NIPER, ICMR, CDSCO, CSIR, BIRAC, NPPA. Each does something distinct — education and research, medical research, drug regulation, industrial research, biotech funding, price control respectively — and a question naming one and asking its function is close to guaranteed.
The third is technical vocabulary, which is where this release is unusually rich. NCE, NBE, biosimilar, complex generic, CAR-T, organoid, exosome, microfluidics, AMR. Candidates are not expected to be biochemists, but they are expected to know which term denotes a novel molecule and which denotes a copy — because that distinction is the entire policy argument.
A fourth pattern worth preparing deliberately is the economics of research funding: why markets under-provide antibiotics, orphan drugs and vaccines for diseases of the poor, and what instruments governments use in response. This reasoning transfers directly to questions on AMR, rare diseases and pandemic preparedness, which appear every cycle.
Preparing for CDS/OTA? For any research scheme, learn the outlay, the implementing department, and the stage of the pipeline it funds. The third of those is what distinguishes otherwise identical-sounding schemes, and it is increasingly what questions turn on. Build the base with our CDS/OTA study material, follow the daily CDS current affairs, and prepare with our faculty in the upcoming Cavalier courses in Delhi.
✍️ Written by The Cavalier — Science and technology desk at The Cavalier. Reviewed by the Cavalier Faculty Desk.